BTK and leukemia: Similarly, the key functions of AKR1C3 in the metabolism of prostaglandins and sex hormones have been related to the development of leukaemia [10,11] and hormone-related tumours [12,13], respectively; thus, AKR1C3 targeting by BTK inhibitors may also counteract carcinogenesis in those tissues overexpressing AKR1C3.